Literature DB >> 35935398

Extrapulmonary sarcoidosis involving only the heart and guts: a case report.

Shun Sasaki1, Takaharu Hayashi1, Emi Tateishi2, Yoshiharu Higuchi1.   

Abstract

Background: The respiratory tract is the most commonly affected organ system in sarcoidosis. Purely extrapulmonary sarcoidosis is rare. There have been no reports of extrapulmonary sarcoidosis with lesions only in the heart and guts. Case summary: A 19-year-old male was admitted for chest symptoms accompanied by remarkably elevated troponin T and creatinine kinase levels. Electrocardiogram (ECG) showed sinus rhythm with a right bundle branch block, broad ST segment elevation, and abnormal Q waves. Endoscopic biopsy revealed granuloma formation in the transverse colon. Based on multimodal imaging, we made a clinical diagnosis of extrapulmonary sarcoidosis involving only the heart and guts. One year of immunosuppressive therapy with prednisolone resolved the inflammation in the guts but not in the heart. He experienced runs of sustained ventricular tachycardia with loss of consciousness and was admitted to our hospital again. The addition of methotrexate markedly reduced cardiac accumulation of fluorodeoxyglucose. No life-threatening ventricular arrhythmias have been recorded afterwards. Discussion: This unusual case of cardiac sarcoidosis not only involved rare lesions only in the heart and guts but also presented with ST elevation on ECG. This case suggests that the gastrointestinal tract is a site of effective antigen capture outside of the respiratory tract that can affect the heart.
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  Cardiac sarcoidosis; Case report; Electrocardiogram; Gut; Immunosuppressive therapy

Year:  2022        PMID: 35935398      PMCID: PMC9350830          DOI: 10.1093/ehjcr/ytac306

Source DB:  PubMed          Journal:  Eur Heart J Case Rep        ISSN: 2514-2119


The acute phase of cardiac sarcoidosis (CS) can involve ST segment elevation on electrocardiogram. CS can coexist with intestinal lesions in purely extrapulmonary sarcoidosis. The combination of a corticosteroid and methotrexate is effective when the effect of initial corticosteroid treatment for CS is insufficient.

Introduction

Sarcoidosis is a systemic inflammatory disease defined histologically by the formation of non-caseating granulomas that can affect any organ.[1] The lung is the most frequently affected organ, in ∼90% of patients and 8.3% of patients only have extrapulmonary manifestations.[2] Several diseases resemble sarcoidosis with respect to the formation of granulomas, such as tuberculosis, fungal infections, parasitic diseases, and inflammatory bowel disease (IBD), especially Crohn’s disease.[3] Of note, IBD is rarely complicated by myocarditis, but if it occurs, differentiation from cardiac sarcoidosis (CS) is difficult. Clinically recognizable gastrointestinal involvement in sarcoidosis is uncommon, occurring in 0.1–1.6% of patients.[4] There have been no reports of CS complications with gastrointestinal lesions and no lung, skin, or liver involvement. Here, we report a rare case of extrapulmonary sarcoidosis only involving lesions in the heart and guts, which are uncommon sites.

Case presentation

A19-year-old male with sudden chest discomfort was admitted to the hospital. He had no past medical history. He did not have bloody stools or symptoms of upper respiratory infection before the onset of chest discomfort. He complained of general fatigue and shortness of breath upon exertion. Physiological examination findings were not noteworthy; no skin lesions were noted, blood pressure was 104/54 mmHg, heart rate was 67 beats per minute, and oxygen saturation was 99% on room air. Careful follow-up was performed without inotropic therapy. The initial electrocardiogram (ECG) showed sinus rhythm with a right bundle branch block, ST segment elevation in II, III, aVF, V4, V5, and V6, and abnormal Q waves in the same leads (). Peripheral blood tests revealed remarkably elevated troponin T and creatinine kinase levels (). Echocardiography demonstrated moderate left ventricular hypertrophy accompanied by oedema and left ventricular ejection fraction (LVEF) of 42% with patchy areas of reduced wall motion. Coronary angiography did not reveal significant stenosis (see Supplementary material online, ). Patchy areas of reduced wall motion were demonstrated by LV angiography (see Supplementary material online, and ). Endomyocardial biopsy from the right ventricular septum showed no pathological findings that were consistent with myocarditis (). Subsequent tests reported high levels of soluble interleukin-2 receptor and lysozyme (). Cardiac magnetic resonance (CMR) with contrast revealed myocardial late gadolinium enhancement (LGE) predominantly on the epicardial side of the posterolateral wall (). Fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) revealed fluorodeoxyglucose accumulation in the same regions as LGE detected with CMR () and in the transverse colon and sigmoid colon ( and ), but there was no abnormal accumulation in the respiratory tracts. Faecal occult blood was positive, so colonoscopy was performed. Inflammatory changes were observed in the transverse colon (). Epithelioid granulomas were found in a biopsy specimen from the transverse colon (). Unusual electrocardiogram findings for cardiac sarcoidosis. Electrocardiogram on admission showed significant ST elevation in II, III, aVF, V5, and V6 accompanied by right bundle branch block. Cardiac findings compatible with cardiac sarcoidosis. (A) Endomyocardial specimens from the right ventricular septum showed no invasion of lymphocytes and no necrosis. Scale bar represents 250 μm. (B) Cardiac magnetic resonance with contrast showed myocardial late gadolinium enhancement predominantly on the epicardial side of the posterolateral wall. (C) Positron emission tomography revealed focal fluorodeoxyglucose uptake in the posterolateral wall of the left ventricle. Granulomas in the transverse colon. (A, B) Fluorodeoxyglucose uptake was detected in the transverse to sigmoid colon. (C) Colonoscopy revealed inflammatory changes in the transverse colon. The green arrow shows the area biopsied. (D) Epithelioid granulomas were found in the biopsy tissue from the transverse colon. The white arrow shows a granuloma. Scale bar represents 100 μm. Laboratory findings on admission First colums represented each inspection items, second colums were reference ranges and third colums were each values. WBC, white blood cells; RBC, red blood cells; Hb, haemoglobin; Neut, neutrophil; Eo, eosinophil; CK, creatine kinase; CK-MB, creatine kinase muscle and brain; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; Cr, creatinine; Ca, calcium; CRP, C-reactive protein; sIL2R, soluble interleukin2 recepter; ACE, angiotensin-converting enzyme. Based on these findings, we made a clinical diagnosis of active CS. We administered oral prednisolone (30 mg/day). The dose of prednisolone was decreased by 5 mg each month. At 6-month follow-up, LVEF (57%), and follow-up colonoscopy revealed significant resolution of inflammation. When PET was performed 1 year later, there was still strong accumulation of FDG in the heart ( and ). After the examination, the patient experienced sudden runs of sustained ventricular tachycardia with loss of consciousness at rest. He was admitted to our hospital again. We performed implantable cardioverter-defibrillator placement. At 4 months after the addition of methotrexate (8 mg/week), there was markedly less cardiac accumulation of FDG ( and ). Eight months have passed since the addition of methotrexate, there is no episode of heart failure admission nor shock therapy. Sustained uptake of fluorodeoxyglucose in the chronic phase, which decreased with methotrexate. (A) Left panel: fusion computed tomography before the start of prednisolone showing strong accumulation of fluorodeoxyglucose in the heart. Centre panel: accumulation of fluorodeoxyglucose 1 year later, with little improvement. Right panel: the addition of methotrexate markedly reduced cardiac accumulation of fluorodeoxyglucose. (B) Comparison of chronic phase uptake during fluorodeoxyglucose based on standard uptake values before treatment (left), prior to (centre) and after (right) the addition of methotrexate.

Discussion

The diagnosis of CS is challenging. We could not detect granulomas with endomyocardial biopsy because we could not biopsy from the affected areas observed with CMR or PET. Based on endoscopic findings and the histological finding of non-caseating epithelioid granulomas in the transverse colon, intestinal lesions were diagnosed as sarcoidosis. ECG findings on admission were interesting in this case because CS is often accompanied by conduction abnormalities and ventricular arrhythmias.[1] Few reports have described ST segment elevation. It might reflect different action potential configurations within the LV wall which were made by inflammation on the epicardial side of the myocardium.[5,6] Although the ECG findings were unusual, LV angiography and laboratory examinations were helpful for making the diagnosis. In addition to the presence of granulomas, the Heart Rhythm Society criteria were met: (i) abnormal uptake on 18F-FDG and (ii) LGE on CMR. After 1 year of prednisolone, life-threatening ventricular tachycardia, which is a major criterion, occurred, strengthening the support for the diagnosis of CS.[7] The addition of methotrexate is effective when initial corticosteroid treatment for CS is insufficient.[8] There are several reports of myocarditis associated with Crohn's disease. The onset of myocarditis reportedly occurs during the course of Crohn's disease.[9] Furthermore, endoscopy did not show longitudinal ulcers, a cobblestone appearance, or discontinuous lesions; there were few findings characteristic of Crohn's disease. A life-threatening arrhythmia was observed after 1 year of prednisolone treatment, which is consistent with sarcoidosis. The clinical course of sarcoidosis is more diverse than previously thought. Although the immunopathogenesis of sarcoidosis is currently unknown, most believe that it is an antigen-driven disease.[10] In extrapulmonary sarcoidosis, the skin is the most common organ involved, found in nearly one-half of patients.[2] The low prevalence of gastrointestinal involvement seems somewhat strange because the gastrointestinal tract is frequently exposed to many antigens.[4] This low prevalence might be due to insufficient scrutiny because of poorly described abdominal symptoms. Although sarcoidosis with gastrointestinal involvement is rare, this case suggests that the gastrointestinal tract can be an effective site of antigen capture outside of the respiratory tract. The details of the relationships between the heart and gastrointestinal tract are not well known, but this case implies an immunological link between them.

Lead author biography

Shun Sasaki is a Medical doctor at Osaka Police Hospital in Japan. Dr. Sasaki graduated from Tohoku University in 2016.

Supplementary material

Supplementary material is available at European Heart Journal – Case Reports online. Click here for additional data file.
Admission (Day 1)Left ventricular angiography revealed patchy areas of reduced wall motion. Endomyocardial biopsy showed no abnormal findings.
Day 2Cardiac enzyme levels peaked: peak creatine kinase, 8110 U/L; peak creatine kinase muscle and brain, 803 U/L.
Day 5Abdominal computed tomography showed para-aortic lymphadenopathy.
Day 7Cardiac magnetic resonance imaging with contrast revealed myocardial late gadolinium enhancement.
Day 30Colonoscopy revealed inflammatory changes in the transverse colon. Endoscopic biopsy revealed epithelioid granulomas.
Day 46Fluorodeoxyglucose accumulated in the heart and guts.
Day 49We started prednisone.
6 months after dischargeFollow-up colonoscopy revealed resolution of inflammatory changes in the guts.
12 months afterFluorodeoxyglucose accumulation in the heart remained strong. The patient experienced sustained ventricular tachycardia. An implantable cardioverter-defibrillator implantation was performed. We added methotrexate.
17 months afterThe addition of methotrexate remarkably decreased the accumulation of fluorodeoxyglucose in the heart.
20 months afterThere is no episode of shock therapy by the implantable cardioverter-defibrillator.
Table 1

Laboratory findings on admission

Laboratory data (on admission)
WBC (/μL)3500–980011 600
RBC (10*9/μL)4.3–5.74.47
Hb (g/dL)13.5–17.613.1
PLT (10*3/μL)131–362335
Neut (%)30.0–75.083.4
Eo (%)0–100.3
CK (U/L)30–2006581
CK-MB (U/L)25>717
AST (U/L)10–33760
ALT (U/L)6–35110
LDH (U/L)110–225854
BUN (mg/dL)8.4–20.414.2
Cr (mg/dL)0.6–1.00.99
Ca (mg/dL)8.8–10.49.5
CRP (mg/dL)0.35>0.72
Troponin T (ng/mL)0.1>>10
sIL2R (U/mL)157–474872
Lysozyme (μg/mL)5.0–10.211.8
ACE (U/L)7.0–25.015.9

First colums represented each inspection items, second colums were reference ranges and third colums were each values.

WBC, white blood cells; RBC, red blood cells; Hb, haemoglobin; Neut, neutrophil; Eo, eosinophil; CK, creatine kinase; CK-MB, creatine kinase muscle and brain; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; Cr, creatinine; Ca, calcium; CRP, C-reactive protein; sIL2R, soluble interleukin2 recepter; ACE, angiotensin-converting enzyme.

  10 in total

Review 1.  Sarcoidosis.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki; Alvin S Teirstein
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

2.  Intramural inflammation as a cause of transient ST-segment elevation in a patient of cardiac sarcoidosis.

Authors:  Kenichi Iijima; Masaomi Chinushi; Hiroshi Furushima; Yoshifusa Aizawa
Journal:  Europace       Date:  2011-08-27       Impact factor: 5.214

3.  HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.

Authors:  David H Birnie; William H Sauer; Frank Bogun; Joshua M Cooper; Daniel A Culver; Claire S Duvernoy; Marc A Judson; Jordana Kron; Davendra Mehta; Jens Cosedis Nielsen; Amit R Patel; Tohru Ohe; Pekka Raatikainen; Kyoko Soejima
Journal:  Heart Rhythm       Date:  2014-05-09       Impact factor: 6.343

4.  Crohn's colitis-induced myocarditis.

Authors:  Rashad J Belin; Ahmadreza Ghasemiesfe; James Carr; Frank H Miller; Carolina Parada; Nausheen Akhter
Journal:  J Cardiol Cases       Date:  2016-04-07

Review 5.  Sarcoidosis Involving the Gastrointestinal Tract: Diagnostic and Therapeutic Management.

Authors:  Pilar Brito-Zerón; Khurram Bari; Robert P Baughman; Manuel Ramos-Casals
Journal:  Am J Gastroenterol       Date:  2019-08       Impact factor: 10.864

6.  Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions.

Authors:  Sonoko Nagai; Takafumi Yokomatsu; Kiminobu Tanizawa; Kohei Ikezoe; Tomohiro Handa; Yutaka Ito; Shunpei Ogino; Takateru Izumi
Journal:  Intern Med       Date:  2014       Impact factor: 1.271

Review 7.  Sarcoidosis.

Authors:  Dominique Valeyre; Antje Prasse; Hilario Nunes; Yurdagul Uzunhan; Pierre-Yves Brillet; Joachim Müller-Quernheim
Journal:  Lancet       Date:  2013-10-01       Impact factor: 79.321

8.  Detection of myocardial damage in patients with sarcoidosis.

Authors:  Manesh R Patel; Peter J Cawley; John F Heitner; Igor Klem; Michele A Parker; Wael A Jaroudi; Trip J Meine; James B White; Michael D Elliott; Han W Kim; Robert M Judd; Raymond J Kim
Journal:  Circulation       Date:  2009-11-02       Impact factor: 29.690

9.  Clinical Features of Extrapulmonary Sarcoidosis Without Lung Involvement.

Authors:  Walter Ennis James; Efstratios Koutroumpakis; Biplab Saha; Alireza Nathani; Leahruth Saavedra; Recai M Yucel; Marc A Judson
Journal:  Chest       Date:  2018-02-14       Impact factor: 9.410

10.  A life-threatening small bowel obstruction as onset of an unknown sarcoidosis: A case report.

Authors:  Gregorino Paone; Alessia Steffanina; Giulia De Rose; Giacomo Leonardo; Daniele Colombo; Paolo Ricci; Francesco Sabetta; Francesco Vaccaro; Edoardo Rosato; Paolo Palange
Journal:  Respir Med Case Rep       Date:  2021-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.